Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03781934
Previous Study | Return to List | Next Study

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03781934
Recruitment Status : Recruiting
First Posted : December 20, 2018
Last Update Posted : February 11, 2022
Sponsor:
Information provided by (Responsible Party):
Medivir

Brief Summary:
This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma Liver Metastases Drug: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab Drug: MIV-818 (fostroxacitabine bralpamide) + lenvatinib Phase 1 Phase 2

Detailed Description:
This study will be conducted in three phases. The initial phase, 1a, will enroll up to 12 subjects and include a total of one dose escalation per patient. Once pre-defined criteria for starting phase 1b monotherapy has been met among the enrolled patients in phase 1a, the next phase of the study will be initiated. Phase 1b monotherapy will enroll up to 30 patients in a 3+3 design with interpatient dose escalations. All dose escalation decisions will be made by a safety review committee that will meet regularly during the study conduct. When the MTD has been established, the SRC will provide a RP2D for monotherapy. Phase 1b combination constitutes an interpatient dose escalation to identify the RP2D for MIV-818 when used in combination with 1) lenvatinib and 2) pembrolizumab therapy. This part of the study will enroll up to 36 patients in a 3+3 design with interpatient dose escalations. Safety review will be performed by the SRC to determine the RP2D of MIV 818 for use in combination with lenvatinib and pembrolizumab. The SRC may recommend that the selected dose of MIV-818 is further evaluated in up to 30 patients in the Phase 2a expansion part of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 102 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Intrapatient dose escalations continuing into interpatient dose escalations to end with dose expansion cohorts.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations
Actual Study Start Date : September 5, 2018
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : May 31, 2023


Arm Intervention/treatment
Experimental: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
Phase 2a expansion cohort HCC
Drug: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
MIV-818 - oral capsules; pembrolizumab - IV

Experimental: MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Phase 2a expansion cohort HCC
Drug: MIV-818 (fostroxacitabine bralpamide) + lenvatinib
MIV-818 - oral capsules; lenvatinib - oral capsules




Primary Outcome Measures :
  1. Incidence and Severity of Adverse Events (AEs) [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Percentage of participants with an adverse event, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0

  2. Incidence and magnitude of clinically significant changes in red blood cell count, white blood cell count and platelet count [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Change from baseline

  3. Incidence and magnitude of clinically significant changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Change from baseline

  4. Incidence and magnitude of clinically significant changes in bilirubin [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Change from baseline

  5. Incidence of clinically significant changes in vital sign - Systolic and diastolic blood pressure [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Millimeter of mercury (mmHg)

  6. Incidence of clinically significant changes in vital sign - Pulse rate [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Beats per minute (BPM)

  7. Incidence of clinically significant changes in vital sign - Body Temperature [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Celsius (°C)

  8. Incidence of clinically significant changes in vital signs - Weight [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    Kilograms (kg)

  9. Incidence of clinically significant changes in ECGs [ Time Frame: Participants monitored throughout treatment period and during follow-up, up to 6 months ]
    QT interval (milli second (ms))


Secondary Outcome Measures :
  1. Preliminary efficacy by means of RECIST evaluation [ Time Frame: Participants monitored throughout treatment period every 6 weeks until disease progression, up to 6 months ]
    1. ORR will be assessed by monitoring tumor response and progression using RECIST v1.1
    2. ORR will be assessed by monitoring tumor response and progression using mRECIST
    3. ORR will be assessed by monitoring tumor response and progression using RECIST v 1.1 in liver lesions only

  2. Plasma levels of α fetoprotein (AFP) [ Time Frame: Participants monitored throughout treatment period every 6 weeks until disease progression, up to 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Male or female ≥ 18 years of age on the day of signing informed consent.
  2. Able to understand and voluntarily sign a written informed consent and is willing, and able, to comply with the protocol requirements.
  3. Must have measurable disease based on RECIST v1.1 as determined by the site study team. Must have at least 1 target lesion in the liver. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  4. Must have a Child-Pugh A status for Phase 1a and a Child-Pugh A or B status for Phase 1b and 2a. SRC discretion to restrict to Child-Pugh A status for Phase 1b and 2a.
  5. Must have an ECOG performance status of 0 or 1 at Screening.
  6. Must have life expectancy of > 12 weeks in the investigator's opinion.
  7. Must have ALT and AST ≤ 5.0 × upper limit of normal (ULN) at Screening.
  8. Must have total bilirubin (TBil) ≤ 3.0 mg/dL at Screening.
  9. Must have adequate renal function with estimated creatinine clearance

    ≥ 60 mL/min (based on Cockcroft and Gault formula or similar) at Screening

  10. Must have platelets ≥ 75,000/mL at Screening.
  11. Must have International Normalized Ratio (INR) ≤ 1.7 at Screening. Female who is postmenopausal, OR Female who is of childbearing potential (postmenarchal) who agrees to use a highly efficient method of contraception (ie, a method with less than 1% failure rate [eg, sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner or combined birth control pills]) from Screening until 90 days after the final dose of MIV-818.

OR Male who agrees to use condoms from Screening until 90 days after the final dose of MIV-818.

OR Male with a female partner of childbearing potential (WOCBP) who is using a highly efficient method of contraception as described above.

13. WOCBP must have a negative serum pregnancy test at Screening and negative (serum or urine) pregnancy test within 72 h before the first study drug dose.

Phase 1a and 1b specific Inclusion Criteria:

14. Must have progressed on or are intolerant of standard therapy with:

  1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or
  2. Histologically or cytologically confirmed iCCA, or
  3. Liver metastases from colon, rectal, or gastric solid tumors with limited extrahepatic tumor burden (any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).

Phase 1b Monotherapy-specific Inclusion Criterion:

15. Must have:

  1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or
  2. Histologically or cytologically confirmed iCCA, or
  3. Liver metastases from solid tumors, with limited extrahepatic tumor burden (i.e. no brain or bone metastases), any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).

    Combination therapy-specific Inclusion Criterion:

    16. Must have histologically or cytologically confirmed HCC that is considered advanced or unresectable, i.e. not suitable for either surgery, radiofrequency ablation (RFA) or loco-regional therapies (patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and medical monitor). Patients with fibrolamellar HCC or a mixed HCC and iCCA will be excluded.

    17. Must have progressed on or are intolerant of 1st line standard therapy for HCC and are now candidates for lenvatinib or pembrolizumab treatment.

    Exclusion Criteria:

    1. Tumor volume exceeding 50% of liver.
    2. History of previous malignancy within the last 5 years except basal cell carcinoma or carcinoma in situ in solid organ.
    3. Known CNS or brain metastases, unless previously treated and stable for 3 months.
    4. Ongoing significant disease other than target disease as judged by the investigator to compromise the patients' ability to complete this study.
    5. History of solid organ transplant or bone marrow transplant.
    6. Receiving immunosuppressive therapy including oral corticosteroids.
    7. Active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) and patients with active hepatitis C (eg, hepatitis C RNA is [qualitative] detected).
    8. Positive human immunodeficiency virus (HIV) infection.
    9. Poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.
    10. Symptomatic encephalopathy within 3 months prior to Screening and/or requirement for medication for encephalopathy.
    11. Esophageal variceal bleeding within 2 weeks prior to Screening.
    12. Receiving prior anticancer therapy within 4 weeks prior to first dose of MIV-818.
    13. Receiving any other investigational agent within 4 weeks prior to Screening
    14. Enrolled in another clinical study with an investigational drug.
    15. Presence of residual toxicities of CTCAE Grade > 1 after prior anticancer therapy within 2 weeks of first treatment with MIV-818, except for alopecia.
    16. History of allergic reactions attributed to compounds of similar chemical or biological composition to MIV-818.
    17. HCC of diffuse infiltrative type.
    18. Receiving drugs that are extensively metabolized by CYP3A4.

      Combination therapy-specific Exclusion Criteria:

      Patients are excluded from combination therapy parts of this study if any of the following criteria are met:

    19. Patients with a diagnosis of fibrolamellar HCC.
    20. Received ≥2 lines of therapy for the treatment of advanced HCC.
    21. Systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg despite optimal anti-hypertensive therapy and with no change in anti hypertensive agents within the last 1 week prior to Screening.
    22. Proteinuria > 1g / 24 hours. Patients with > 1+ proteinuria on dipstick testing will need a 24-hour urine protein measured to exclude proteinuria > 1g / 24 hours.
    23. Bleeding disorders, on anti-coagulation drugs or anti-platelet therapies.
    24. Any interventional treatment for esophageal varices required within 28 days of study treatment.
    25. Hepatic encephalopathy in the last 6 months.
    26. QTc interval is greater than 480 milliseconds at Screening.
    27. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
    28. Has an active infection requiring systemic therapy.

      Exclusion criteria applicable to pembrolizumab cohort only:

    29. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to planned start of study therapy.
    30. Presence of known active tuberculosis (TB; Bacillus tuberculosis).
    31. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
    32. Known history of, or any evidence of active, non-infectious pneumonitis or has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03781934


Contacts
Layout table for location contacts
Contact: Medivir AB +46854683100 Clinical@medivir.com

Locations
Layout table for location information
Belgium
Antwerp University Hospital Completed
Antwerp, Belgium, 2650
University Hospitals Gasthuisberg Completed
Leuven, Belgium, 3000
United Kingdom
Beatson West of Scotland Cancer Care Recruiting
Glasgow, United Kingdom, G12 0YN
Contact: Jeff Evans, Professor    +44 (0) 141 301 7073    jeff.evans@ggc.scot.nhs.uk   
Contact: Laura Cunningham, Nurse    +44 (0) 141 301 7229    laura.cunningham4@ggc.scot.nhs.uk   
Guy's Hospital, Oncology and Clinical Trials Recruiting
London, United Kingdom, SE1 9RT
Contact: Debashis Sarker, MD, PhD    +4420871887188 ext 5383    debashis.sarker@kcl.ac.uk   
Contact: Michael Flanagan, Nurse    +442071888103    michael.flanagan@gstt.nhs.uk   
Northern Institute for Cancer Research Recruiting
Newcastle Upon Tyne, United Kingdom, NE2 4HH
Contact: Ruth Plummer, Professor    +44 (0)191 213 6161    ruth.plummer@newcastle.ac.uk   
Contact: Katherine Stevensson, Nurse    +44 191 213 8437    katherine.stevensson@nuth.nhs.uk   
Chruchill Hospital, Cancer and Haematology Centre Completed
Oxford, United Kingdom, OX3 7LE
Sponsors and Collaborators
Medivir
Investigators
Layout table for investigator information
Principal Investigator: Ruth Plummer, Professor Northern Institute for Cancer Research, Newcastle
Layout table for additonal information
Responsible Party: Medivir
ClinicalTrials.gov Identifier: NCT03781934    
Other Study ID Numbers: MIV-818-101/201
First Posted: December 20, 2018    Key Record Dates
Last Update Posted: February 11, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Cholangiocarcinoma
Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Pembrolizumab
Lenvatinib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action